GSK innovation fund scouts Canadian biotechs; Arena raising cash; Gamida Cell raises $10M;

 @FierceBiotech: MIT: Staggering cancer drugs can make them more effective. More | Follow @FierceBiotech

 @RyanMFierce: It's only a matter of time before fat taxes are everywhere. Obesity costs too much, and taxes on smokes paved the way. Report | Follow @RyanMFierce

 @JohnCFierce: Stealth no more: Ra Pharma in Cambridge nails $8.6M venture tranche, targets hereditary angioedema for the lead. Article | Follow @JohnCFierce

> GSK ($GSK) execs are talking up their $50 million "innovation" fund, which is bankrolling early-stage biotechs in the Quebec area. Story

> With its prospects for lorcaserin looking good these days, Arena Pharmaceuticals ($ARNA) says it will raise some extra cash through the sale of common stock. Report

> Gamida Cell has raised $10 million to back the launch of its lead cell therapy product. Report

> Pfizer ($PFE) says Torisel flunked a Phase III comparison study with Nexavar for renal cell carcinoma. Release

Pharma News

 @FiercePharma: Patients 'waiting up to nine years' for NICE to approve drugs, a U.K. study finds--TelegraphStory | Follow @FiercePharma

> Top 10 Best-selling Cancer Drugs in 2011. Special Report

> New discount persuades NICE to bless J&J's Zytiga. News

> U.K. report says NICE drags its feet on drug approvals. Article

Medical Device News

 @FierceMedDev: Folks, the clock is ticking. Get your nominations in for the 15 fiercest device developers. Survey | Follow @FierceMedDev

> NeuroSigma buys patents that advance TFN stents. Report

> OraSure's OTC HIV test wins crucial FDA panel backing. Article

> Medtronic's Resolute Integrity stent gains CE mark for 7 new indications. More

> St. Jude wins CE mark for hypertension treatment device. Item

Drug Delivery News

 @DamianFierce: Using self-assembling DNA tubes, Harvard researchers plan to effectively deliver drugs to cells. News | Follow @DamianFierce

> UNC researchers craft siRNA platform that can switch its solubility. Report

> MIT: Staggering cancer drugs can make them more effective. Story

> Japanese firm buys Altea's assets, plans to launch transdermal tech. Article

> D. Medical signs worldwide marketing deal for insulin-delivery tech. Item

Biomarkers News

> Genes tag schizophrenia risk. More

> Proteins in a drop of fluid mark osteoarthritis risk. Report

> Early pancreatic biomarker could spot killer disease. Article

> Gene IDs fast-onset Parkinson's disease. Story

And Finally… Investigators say they successfully slowed down the biological clock in mice in a proof of principle study that spurred expression of telomerase. Release

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.